Literature DB >> 3337268

Effect of continuous infusions of CCK-8 on food intake and body and pancreatic weights in rats.

L Lukaszewski1, M Praissman.   

Abstract

The ability of cholecystokinin (CCK) to act as a long-term satiety factor was assessed by its continuous infusion into the jugular veins of rats. Animals receiving a low dose of cholecystokinin octapeptide (CCK-8) (0.6 microgram CCK-8.kg body wt-1.h-1) did not show any significant differences in body weight changes or in food consumption from rats receiving saline and a group of unoperated controls over the 7-day infusion period. A 19.3-fold greater dose of CCK-8 (11.6 micrograms.kg body wt-1.h-1) did cause a significant decline in food consumption for the first 4 days compared with saline-infused rats (P less than 0.05) and unoperated controls (P less than 0.01). Rats receiving a high dose of CCK gained weight at a slower rate than rats receiving saline, but this effect lasted only 2 days and was not significant. Pancreatic growth was used as an indirect measure of elevated CCK levels in these animals. The infusion of 0.6 microgram CCK-8.kg body wt-1.h-1 did not lead to sufficiently elevated peptide levels to promote pancreatic growth. In contrast, those rats receiving a high dose of CCK-8 had significantly greater pancreatic weights (P less than 0.01) compared with saline-treated rats and unoperated controls. These results indicate that CCK-8, when administered continuously and in a large enough dose, can suppress food intake in rats for a period of several days before losing its effectiveness.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3337268     DOI: 10.1152/ajpregu.1988.254.1.R17

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

Review 1.  New advances in models and strategies for developing anti-obesity drugs.

Authors:  Gilbert W Kim; Jieru E Lin; Erik S Blomain; Scott A Waldman
Journal:  Expert Opin Drug Discov       Date:  2013-04-29       Impact factor: 6.098

Review 2.  Regulation of appetite to treat obesity.

Authors:  Gilbert W Kim; Jieru E Lin; Michael A Valentino; Francheska Colon-Gonzalez; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

3.  Effects of protease and non-starch polysaccharide enzyme on performance, digestive function, activity and gene expression of endogenous enzyme of broilers.

Authors:  Lin Yuan; Mingfa Wang; Xiaotu Zhang; Zhixiang Wang
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

4.  Mechanisms contributing to the differential haemodynamic effects of bombesin and cholecystokinin in conscious, Long Evans rats.

Authors:  P J Janssen; S M Gardiner; A M Compton; T Bennett
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

5.  Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity.

Authors:  Michael A Valentino; Francheska Colon-Gonzalez; Jieru E Lin; Scott A Waldman
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

Review 6.  Obesity pharmacotherapy: what is next?

Authors:  Francheska Colon-Gonzalez; Gilbert W Kim; Jieru E Lin; Michael A Valentino; Scott A Waldman
Journal:  Mol Aspects Med       Date:  2012-10-24

7.  Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats.

Authors:  Roger D Reidelberger; Alvin C Haver; Prasanth K Chelikani; James L Buescher
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-06-11       Impact factor: 3.619

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.